Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
- PMID: 11287972
- DOI: 10.1056/NEJM200104053441401
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
Abstract
Background: BCR-ABL is a constitutively activated tyrosine kinase that causes chronic myeloid leukemia (CML). Since tyrosine kinase activity is essential to the transforming function of BCR-ABL, an inhibitor of the kinase could be an effective treatment for CML.
Methods: We conducted a phase 1, dose-escalating trial of STI571 (formerly known as CGP 57148B), a specific inhibitor of the BCR-ABL tyrosine kinase. STI571 was administered orally to 83 patients with CML in the chronic phase in whom treatment with interferon alfa had failed. Patients were successively assigned to 1 of 14 doses ranging from 25 to 1000 mg per day.
Results: Adverse effects of STI571 were minimal; the most common were nausea, myalgias, edema, and diarrhea. A maximal tolerated dose was not identified. Complete hematologic responses were observed in 53 of 54 patients treated with daily doses of 300 mg or more and typically occurred in the first four weeks of therapy. Of the 54 patients treated with doses of 300 mg or more, cytogenetic responses occurred in 29, including 17 (31 percent of the 54 patients who received this dose) with major responses (0 to 35 percent of cells in metaphase positive for the Philadelphia chromosome); 7 of these patients had complete cytogenetic remissions.
Conclusions: STI571 is well tolerated and has significant antileukemic activity in patients with CML in whom treatment with interferon alfa had failed. Our results provide evidence of the essential role of BCR-ABL tyrosine kinase activity in CML and demonstrate the potential for the development of anticancer drugs based on the specific molecular abnormality present in a human cancer.
Comment in
-
Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia.N Engl J Med. 2001 Apr 5;344(14):1084-6. doi: 10.1056/NEJM200104053441409. N Engl J Med. 2001. PMID: 11287980 No abstract available.
-
Cutaneous reactions to STI571.N Engl J Med. 2001 Aug 23;345(8):618-9. doi: 10.1056/NEJM200108233450814. N Engl J Med. 2001. PMID: 11529225 No abstract available.
Similar articles
-
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.N Engl J Med. 2001 Apr 5;344(14):1038-42. doi: 10.1056/NEJM200104053441402. N Engl J Med. 2001. PMID: 11287973 Clinical Trial.
-
Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells.Leukemia. 2001 Mar;15(3):342-7. doi: 10.1038/sj.leu.2402041. Leukemia. 2001. PMID: 11237055 Clinical Trial.
-
Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.Lancet Oncol. 2011 Sep;12(9):841-51. doi: 10.1016/S1470-2045(11)70201-7. Epub 2011 Aug 17. Lancet Oncol. 2011. PMID: 21856226 Clinical Trial.
-
Spotlight on imatinib mesylate in chronic myeloid leukemia.BioDrugs. 2004;18(3):207-10. doi: 10.2165/00063030-200418030-00009. BioDrugs. 2004. PMID: 15161340 Review.
-
[Molecular targeted treatment--new treatment strategy for patients with chronic myeloid leukemia].Rinsho Byori. 2004 Feb;52(2):136-44. Rinsho Byori. 2004. PMID: 15027317 Review. Japanese.
Cited by
-
Treatment-free remission after discontinuation of tyrosine kinase inhibitors in patients with chronic myeloid leukemia in the chronic phase: a systematic review and meta-analysis.Discov Oncol. 2024 Oct 23;15(1):586. doi: 10.1007/s12672-024-01444-9. Discov Oncol. 2024. PMID: 39441428 Free PMC article.
-
Kinome state is predictive of cell viability in pancreatic cancer tumor and cancer-associated fibroblast cell lines.PeerJ. 2024 Aug 28;12:e17797. doi: 10.7717/peerj.17797. eCollection 2024. PeerJ. 2024. PMID: 39221276 Free PMC article.
-
Advances in Personalized Oncology.Cancers (Basel). 2024 Aug 16;16(16):2862. doi: 10.3390/cancers16162862. Cancers (Basel). 2024. PMID: 39199633 Free PMC article. Review.
-
Global burden, risk factor analysis, and prediction study of leukaemia from 1990 to 2030.J Glob Health. 2024 Aug 23;14:04150. doi: 10.7189/jogh.14.04150. J Glob Health. 2024. PMID: 39173170 Free PMC article.
-
Biopolymeric nanocarriers in cancer therapy: unleashing the potency of bioactive anticancer compounds for enhancing drug delivery.RSC Adv. 2024 Aug 12;14(35):25149-25173. doi: 10.1039/d4ra03911d. eCollection 2024 Aug 12. RSC Adv. 2024. PMID: 39139249 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous